RGBP · Regen BioPharma, Inc.

Summary

Regen BioPharma, Inc. issued 77,849,847 common shares between February 4, 2026 and February 27, 2026 in satisfaction of $53,474 principal convertible indebtedness, $4,249 accrued interest, and $11,000 fees. The shares were issued under Section 4(a)(2) of the Securities Act without underwriters or general solicitation; as of March 3, 2026, 212,318,424 common shares are issued and outstanding.

Key takeaways

• Issued 77,849,847 common shares from February 4 to February 27, 2026
• Satisfied $53,474 principal convertible indebtedness
• Satisfied $4,249 accrued interest on convertible indebtedness
• Satisfied $11,000 in incurred fees
• Issued pursuant to Section 4(a)(2) of the Securities Act
• 212,318,424 common shares issued and outstanding as of March 3, 2026